← back to search

Tobias Janowitz

Northwell Health ·
Area of research
Oncology · Physiology
Research interest
Research interests include Nutrition and Health in Aging, Cancer Immunotherapy and Biomarkers, Chronic Kidney Disease and Diabetes, and GDF15 and Related Biomarkers.
h-index
31
citations
10,137
works
119
NIH funding
primary concept
email

Recent publications

Hepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice
Nature Metabolism 2025cited by 23position: middledoi
Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies
Cancer Discovery 2025cited by 10position: middledoi
A guideline on the molecular ecosystem regulating ferroptosis
Nature Cell Biology 2024cited by 238position: middledoi
Why do patients with cancer die?
Nature reviews. Cancer 2024cited by 115position: middledoi
Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function
Science 2024cited by 43position: middledoi
Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
JAMA Oncology 2024cited by 19position: lastdoi
Cachexia: A systemic consequence of progressive, unresolved disease
Cell 2023cited by 221position: lastdoi
Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia
Cell Metabolism 2023cited by 100position: lastdoi
Data from CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer
2023cited by 0position: lastdoi
Abstract 1162: Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia
Cancer Research 2023cited by 0position: lastdoi
Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack.
Apollo (University of Cambridge) 2022cited by 64position: middledoi
Neurotensin neurons in the extended amygdala control dietary choice and energy homeostasis
Nature Neuroscience 2022cited by 29position: middledoi
A framework for advancing our understanding of cancer-associated fibroblasts
Nature reviews. Cancer 2020cited by 3,711position: middledoi
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Proceedings of the National Academy of Sciences 2020cited by 253position: middledoi
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
medRxiv 2020cited by 21position: middledoi
CamGFR v2: A New Model for Estimating the Glomerular Filtration Rate from Standardized or Non-standardized Creatinine in Patients with Cancer
Clinical Cancer Research 2020cited by 14position: lastdoi
Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet
Gastroenterology 2019cited by 87position: middledoi
Multicenter Validation of the CamGFR Model for Estimated Glomerular Filtration Rate
JNCI Cancer Spectrum 2019cited by 11position: lastdoi
A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy
Seminars in Oncology 2018cited by 20position: lastdoi
A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway
Journal of Allergy and Clinical Immunology 2018cited by 11position: middledoi
Cancer: The Tumor-Driven Disease of the Host
Cell Metabolism 2018cited by 9position: firstdoi
Validation of a new model for estimating glomerular filtration rate in patients with cancer.
Journal of Clinical Oncology 2018cited by 0position: lastdoi
A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Seminars in Oncology 2017cited by 266position: lastdoi
Connecting the Metabolic and Immune Responses to Cancer
Trends in Molecular Medicine 2017cited by 70position: lastdoi
Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes
Annals of Oncology 2017cited by 32position: lastdoi
Cancer Immunotherapy Trials Underutilize Immune Response Monitoring
The Oncologist 2017cited by 4position: lastdoi
A new model for estimating glomerular filtration rate in patients with cancer.
Journal of Clinical Oncology 2017cited by 3position: firstdoi
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity
Cell Metabolism 2016cited by 361position: middledoi
The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data
Magnetic Resonance Imaging 2014cited by 2position: middledoi
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer
Proceedings of the National Academy of Sciences 2013cited by 1,986position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Duncan I. Jodrell · University of Cambridge9 papers (2012–2019)Claire M. Connell · Cancer Research UK Cambridge Center9 papers (2013–2023)Thomas R. Flint · Cambridge University Hospitals NHS Foundation Trust8 papers (2016–2023)Edward H. Williams · Cancer Research UK Cambridge Center6 papers (2017–2023)Miriam Ferrer · Cancer Research UK Cambridge Center5 papers (2018–2025)Douglas T. Fearon · Athens University of Economics and Business5 papers (2013–2022)Simon Tavaré · Ludwig Cancer Research5 papers (2017–2023)Eileen White · Rutgers, The State University of New Jersey4 papers (2023–2025)Ian Beh · Cambridge University Hospitals NHS Foundation Trust4 papers (2017–2019)Marcus D. Goncalves · Cornell University4 papers (2023–2025)Andy G. Lynch · University of St Andrews4 papers (2017–2023) · 4 papers (2017–2024) · 3 papers (2019–2023) · 3 papers (2018–2023)Helena Earl · University of Cambridge3 papers (2017–2019)Anthony P. Coll · University of Manchester3 papers (2016–2023)Nicholas J. Bird · Cambridge University Hospitals NHS Foundation Trust3 papers (2019–2023) · 3 papers (2022–2023)Rachel Rubino · Queen's University3 papers (2022–2023) · 3 papers (2019–2023)